期刊文献+

舒利迭对慢性阻塞性肺病肺功能的影响及其临床意义 被引量:8

下载PDF
导出
摘要 目的探讨舒利迭在稳定期COPD中的治疗作用和肺功能深吸气量的测定在慢性阻塞性肺疾病患者中的临床应用价值。方法对49例中重度稳定期COPD患者分别在吸入舒利迭和沙丁胺醇前后进行常规肺功能检测和6min步行试验后肺功能检测,以Borg指数进行呼吸困难的分级。结果吸入舒利迭组FVC、IC和沙丁胺醇组比较有显著升高,FRC、RV两组下降幅度差别有统计学意义;第8周运动后,两组FRC、RV增加幅度较第1天运动后增加幅度降低,舒利迭组的差别有统计学意义;两组FEV1、FVC、IC第8周运动后下降幅度减少,IC差别有统计学意义。运动后,Borg指数的变化与IC的变化呈显著负相关,吸药8周后,步行距离的增加和吸药前后IC的增加(△IC)高度相关。结论舒利迭比沙丁胺醇更能改善COPD患者的呼吸困难等症状,评价支气管扩张剂的疗效时,IC比FEV1更敏感,并能较准确地反映患者呼吸困难的严重程度。
作者 林盪 张兰兰
出处 《中国现代医生》 2008年第35期88-89,共2页 China Modern Doctor
  • 相关文献

参考文献8

  • 1[1]Celli BR,MaNee W,Committee members.Standard for the diagnosis and treatment of patients with COPD:a summary of the ATS/ERS position paper. 被引量:1
  • 2[2]O'Denneli DE,Revill SM,Webb KA.Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary disease[J].Am J Bespir Crit Care Med,2001,164(1):770-777. 被引量:1
  • 3[3]Diaz O,Villafranca C,Ghezzo H,et al.Role of inapiratory Capacity on exercise tolerance in COPD patients with and without tidal exoiratory flow limitation at rest[J].Eur Respir J,2000,16(2):269-275. 被引量:1
  • 4[4]Belman MJ,Botnick WC,Shin JW.Inhaled bronchdilators reduce dynamic hyperinflatian during exercise in patients with chronic obstructive pulmonary disease[J].Am J Bespir Criy Care Med,1996,153(2):967-975. 被引量:1
  • 5叶永青,张孔.舒利迭对慢性阻塞性肺疾病患者肺功能的影响[J].现代预防医学,2005,32(8):902-903. 被引量:21
  • 6[6]Gelb AF,Gutierrez CA,Eeisman IM,et al.Simplified detection of dynamic hyperinflation[J].Chest,2004,126(1):1855-1860. 被引量:1
  • 7李欣,赵建平,陈慧,朱丹,楼雅芳,涂军伟.稳定期慢性阻塞性肺疾病患者深吸气量测定的临床意义[J].中华结核和呼吸杂志,2007,30(1):23-26. 被引量:15
  • 8[8]Matin Jm,Carrizo SJ,Gascon M,et al.Inapiratory Capacity,Dynamic Hyperinflation,Breathlesaness,and Exercise Performance during the 6-Minute-Walk Test in Chronic Obstructive Pulmonary Disease[J].Am J Respir Crit Care Med,2001,163(2):1395-1399. 被引量:1

二级参考文献14

  • 1陈爱欢,陈荣昌,李俊梅,钟南山.呼气相气道内负压法检测呼气流速受限在慢性阻塞性肺疾病中的应用[J].中华结核和呼吸杂志,2006,29(4):236-239. 被引量:6
  • 2www.goldcopd.com.SPECIAL ISSUE: GOLD WORKSHOP REPORT GOLD Newletters . AUG . 8/29/03 . 被引量:1
  • 3Pauwels RA, Buist AS, Calverley PM, et al. On behalf of the GOLD Scientific Committee. Global strategy for the diagnosis, management,and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary [Z] .AmJ Respir Crit Care Med.2001 Apr; 163 (5):1256 - 1276. 被引量:1
  • 4Jarvis B, Markham A.Inhaled salmeterol: a review of its efficacy in chronic obstructive pulmonary disease [J] .Drugs Aging.2001; 18(6): 441 - 72. 被引量:1
  • 5Howarth PH, Beckett P, Dahl R.The effect of long acting beta2 - agonists on airway inflammation in asthmatic patients [ J ] .Respir Med.2000; 94 Supp1 F: S22 - 27. 被引量:1
  • 6Van den Berg NJ.Salmeterol/fluticasone propionate (50/100μg) in combination in a Diskus inhaler (Seretide) is effective and sale in children with asthma [J] .Paediatric Pulmonology.2000, 10 (1): 200. 被引量:1
  • 7Pelaia G, Vatrella A, Cuda G, et al. Molecular mechanisms of corticosteroid actions in chronic inflammatory airway diseases [ J ] .Life Sci.200321; 72 (14): 1549-61. 被引量:1
  • 8Manriquez J,Diaz O,Borzone G,et al.Spirometric reversibility to salbutamol in chronic obstructive pulmonary disease (COPD).Differential effects on FEV1 and on lung volumes.Rev Med Chil,2004,132:787-793. 被引量:1
  • 9Newton MF,O' Donnell DE,Forkert L.Response of lung volumes to inhaled salbutamol in a large population of patients with severe hyperinflation.Chest,2002,121:1042-1050. 被引量:1
  • 10O' Donnell DE,Forkert L,Webb KA.Evaluation of bronchodilator responses in patients with "irreversible"emphysema.Eur Respir J,2001,18:914-920. 被引量:1

共引文献34

同被引文献36

二级引证文献39

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部